Skip to main content
OpenTrials
Completed

NCT Number: NCT03773575

Evaluation of Closed Incision Negative Pressure Dressing (PREVENA) to Prevent Lower Extremity Amputation Wound Complications

This study is a prospective, multi-center, two-arm, unblinded, and randomized controlled trial with a goal of evaluating the impact of a closed incision negative pressure dressing (PREVENA) on incidence of post-operative wound complications and medical costs in patients undergoing lower extremity amputation.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gemelli Hospital, Roma, RM, Italy

Loading trial locations.

About this study

This is a prospective, multi-center, two-arm, unblinded, randomized controlled trial to evaluate the impact of a closed incision negative pressure dressing (PREVENA™ PEEL & PLACE™ Dressing Kit) on incidence of post-operative wound complications in patients undergoing above-the-knee (AKA) or below-the-knee (BKA) amputation. Up to 440 subjects at approximately five (5) participating sites will be randomized to receive either the Prevena dressing or a standard care dressing. The incision will be assessed for complications at post-op day 5 or day 6 and at approximately 30 days after discharge. The primary outcome of this study is reported wound complications, including dehiscence (opening of the incision), seroma, lymph leak, infection (deep or superficial), hematoma (blood clots), ischemia (decreased blood supply), and necrosis (tissue death) A major complication is defined as any wound complication requiring intravenous or oral antibiotics, reoperation and/or hospital readmission. All data (demographics, medical history, and clinical outcomes) will be collected via medical record review

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female adults 18 years or older
  • Patients undergoing above-knee amputation (includes the revision of emergency guillotine amputations)
  • Patients undergoing below-knee amputation (includes the revision of emergency guillotine amputations)
  • Informed Consent signed by patient

Exclusion criteria

  • Minors under 18 years
  • Women who are pregnant or breastfeeding
  • Patients having BOTH legs amputated
  • Patients with sensitivity to silver
  • Unwilling or unable to provide informed consent
  • Inability to comply with planned study procedures

Treatment and study plan

PREVENA™ PEEL & PLACE™ Dressing Kit

Device

In combination with a negative pressure pump (V.A.C. ® Therapy Unit, KCI USA, Inc.), the Prevena dressing is designed to provide negative pressure wound therapy (NPWT) over surgical incisions (incisional NPWT).

Primary outcomes

  1. Overall Rate of Wound Complications

    Time frame: 30 days post procedure

    Presence of any of the following post-procedure:

    • Dehiscence (skin or fascia)
    • Seroma
    • Lymph leak
    • Infection (superficial or deep, using CDC Surgical Site Infection criteria)
    • Hematoma
    • Ischemia
    • Necrosis

Secondary outcomes

  1. Length of Stay (LOS)

    Time frame: 30 days post procedure

    index LOS is defined as days from operation to discharge; 30d LOS is defined as the index LOS plus all readmission days within 30d related to any wound complication

  2. 30-day Return to Operating Room (ROR)

    Time frame: 30 days post procedure

    Reoperation for wound complication within 30 days involving incision and drainage in the operating room; opening the skin to drain a superficial soft tissue infection at bedside or in the office is not considered reoperation

  3. 30-day Hospital Readmissions

    Time frame: 30 days post procedure

    Rehospitalization for wound complication within 30 days

  4. Incidence of Skin Dehiscence

    Time frame: 30 days post procedure

    Individual rates of the incidence of skin dehiscence

  5. Incidence of Fascial Dehiscence

    Time frame: 30 Days

    Individual incidence rate of fascial dehiscence

  6. Incidence of Superficial Skin Infection

    Time frame: 30 days

    Individual incidence of superficial skin infection

  7. Incidence of Deep Skin Infection

    Time frame: 30 days

    Individual incidence of deep skin infection

  8. Incidence of Seroma

    Time frame: 30 Days

    Individual incidence of seroma

  9. Incidence of Hematoma

    Time frame: 30 days

    Individual Incidence of Hematoma

  10. Incidence of Necrosis

    Time frame: 30 Days

    Individual incidence of Necrosis

Sponsors and collaborators

Lead sponsor

Thomas Jefferson University

Other

Collaborators

  • Acelity

Registry information

Acronym: PREVENA-AMP

Important dates

Study start
2019
Primary completion
2024
Study completion
2024
First posted
Dec 12, 2018
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.